» Articles » PMID: 24440181

The Relative Frequency of CFTR Mutation Classes in European Patients with Cystic Fibrosis

Overview
Journal J Cyst Fibros
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2014 Jan 21
PMID 24440181
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

More than 1900 different mutations in the CFTR gene have been reported. These are grouped into classes according to their effect on the synthesis and/or function of the CFTR protein. CFTR repair therapies that are mutation or mutation class specific are under development. To progress efficiently in the clinical phase of drug development, knowledge of the relative frequency of CFTR mutation classes in different populations is useful. Therefore, we describe the mutation class spectrum in 25,394 subjects with CF from 23 European countries. In 18/23 countries, 80% or more of the patients had at least one class II mutation, explained by F508del being by far the most frequent mutation. Overall 16.4% of European patients had at least one class I mutation but this varied from 3 countries with more than 30% to 4 countries with less than 10% of subjects. Overall only respectively 3.9, 3.3 and 3.0% of European subjects had at least one mutation of classes III, IV and V with again great variability: 14% of Irish patients had at least one class III mutation, 7% of Portuguese patients had at least one class IV mutation, and in 6 countries more than 5% of patients had at least one class V mutation.

Citing Articles

Variability in disease severity among cystic fibrosis patients carrying residual-function variants: data from the European Cystic Fibrosis Society Patient Registry.

Mei-Zahav M, Orenti A, Jung A, Kerem E ERJ Open Res. 2025; 11(1.

PMID: 39811546 PMC: 11726569. DOI: 10.1183/23120541.00587-2024.


Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real-Life Study.

Zwitserloot A, Aziz S, Chen Y, Bannier M, Janssens H, Merkus P Pediatr Pulmonol. 2025; 60(1):e27473.

PMID: 39785291 PMC: 11715133. DOI: 10.1002/ppul.27473.


Sex Differences in Sleep Profiles and the Effect of Elexacaftor/Tezacaftor/Ivacaftor on Sleep Quality in Adult People with Cystic Fibrosis: A Prospective Observational Study.

Dietz-Terjung S, Strassburg S, Schulte T, Dietz P, Weinreich G, Taube C Diagnostics (Basel). 2025; 14(24.

PMID: 39767222 PMC: 11675557. DOI: 10.3390/diagnostics14242859.


Systematic deletion of symmetrical exons reveals new therapeutic targets for exon skipping antisense oligonucleotides.

Pena-Rasgado C, Rodriguez-Manriquez E, Dundr M, Bridges R, Hastings M, Michaels W NAR Mol Med. 2024; 1(4):ugae017.

PMID: 39582793 PMC: 11579696. DOI: 10.1093/narmme/ugae017.


Immunomodulatory activity of omadacycline and in a murine model of acute lung injury.

Sanders M, Beringer P mSphere. 2024; 9(11):e0067124.

PMID: 39475317 PMC: 11580420. DOI: 10.1128/msphere.00671-24.